{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:02:22Z","timestamp":1793397742276,"version":"4.5.0"},"reference-count":168,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Behcet\u2019s disease (BD) is a chronic multi-systemic disease characterized by relapsing-remitting oral ulcers, genital ulcers, ocular inflammatory involvements, and numerous other systemic features. Ocular involvements are quite common in BD and may cause severe tissue damage and potentially blindness. Even though the pathogenesis of BD remains ambiguous, growing evidences have shown that genetic factors, environmental triggers and immunological abnormalities play significant roles in its development and progression. Novel biotherapies targeting IFN-\u03b3, TNF-\u03b1 and interleukins have been used in recent years. In this review, we mainly pay attention to the ocular involvement of BD, and discuss the current understanding of mechanisms and advances in therapeutic approaches, especially novel biologics. Finally, we discuss the management in patients with pregnancy.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1206959","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T17:20:11Z","timestamp":1696094411000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Advances in pathogenesis and treatment of ocular involvement in Behcet\u2019s disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Suibin","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baozhao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00665","article-title":"Immunopathogenesis of behcet's disease","volume":"10","author":"Tong","year":"2019","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.640473","article-title":"Pathogenesis of non-infectious uveitis elucidated by recent genetic findings","volume":"12","author":"Takeuchi","year":"2021","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2003.01893.x","article-title":"Prevalence of behcet's disease in istanbul, Turkey","volume":"42","author":"Azizlerli","year":"2003","journal-title":"Int J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/01.icu.0000247411.59213.bb","article-title":"Behcet's disease: general concepts and recent advances","volume":"17","author":"Okada","year":"2006","journal-title":"Curr Opin Ophthalmol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfo.2019.02.002","article-title":"Eye and beh\u00e7et's disease","volume":"42","author":"Ksiaa","year":"2019","journal-title":"J Fr Ophtalmol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"update of the EULAR recommendations for the management of Behcet's syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1985.tb02084.x","article-title":"Familial cases of Behcet's disease","volume":"113","author":"Dundar","year":"1985","journal-title":"Br J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.8.622","article-title":"Familial aggregation of Behcet's disease in Turkey","volume":"59","author":"Gul","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(73)93343-6","article-title":"Letter: HL-A5 and behcet's disease","volume":"2","author":"Ohno","year":"1973","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1982.01030040433013","article-title":"Close association of HLA-Bw51 with Behcet's disease","volume":"100","author":"Ohno","year":"1982","journal-title":"Arch Ophthalmol (Chicago Ill 1960)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1977.01640120088021","article-title":"HLA antigens associated with Behcet's disease","volume":"113","author":"Ersoy","year":"1977","journal-title":"Arch Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2340\/0001555557243245","article-title":"The histocompatibility antigens in patients with Behcet's disease","volume":"57","author":"Haim","year":"1977","journal-title":"Acta Derm Venereol"},{"key":"B13","article-title":"[HLA typing in patients of German origin with recurrent benign aphthosis and Behcet's disease]","volume":"59","author":"Djawari","year":"1984","journal-title":"Z Hautkr"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.45.12.987","article-title":"Behcet's disease in Iraqi patients","volume":"45","author":"Al-Rawi","year":"1986","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.1988.29.3.259","article-title":"A study of HLA antigens in Behcet's syndrome","volume":"29","author":"Lee","year":"1988","journal-title":"Yonsei Med J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.1992.tb01925.x","article-title":"Serological and molecular HLA typing in Italian Behcet's patients: significant association to B51-DR5-DQw3 haplotype","volume":"39","author":"Balboni","year":"1992","journal-title":"Tissue Antigens"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.31.1073","article-title":"Histocompatibility antigens associated with Behcet's disease in northern Han Chinese","volume":"31","author":"Mineshita","year":"1992","journal-title":"Internal Med (Tokyo Japan)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.1999.540308.x","article-title":"HLA class I and II typing of the patients with Behcet's disease in Saudi Arabia","volume":"54","author":"Yabuki","year":"1999","journal-title":"Tissue Antigens"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.1999.540307.x","article-title":"HLA and tumour necrosis factor (TNF) polymorphisms in ocular Behcet's disease","volume":"54","author":"Verity","year":"1999","journal-title":"Tissue Antigens"},{"key":"B20","article-title":"Association of MICA gene and HLA-B*5101 with Behcet's disease in Greece","volume":"40","author":"Yabuki","year":"1999","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.2001.057005457.x","article-title":"HLA class I genotyping including HLA-B*51 allele typing in the Iranian patients with Behcet's disease","volume":"57","author":"Mizuki","year":"2001","journal-title":"Tissue Antigens"},{"key":"B22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1365-3083.2006.01780.x","article-title":"Allelic diversity and affinity variants of MICA are imbalanced in Spanish patients with Behcet's disease","volume":"64","author":"Munoz-Saa","year":"2006","journal-title":"Scandinavian J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200101)44:1<239::AID-ANR31>3.0.CO;2-X","article-title":"Evidence for linkage of the HLA-B locus in Behcet's disease, obtained using the transmission disequilibrium test","volume":"44","author":"Gul","year":"2001","journal-title":"Arthritis Rheum"},{"key":"B24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2174\/1874312901812010070","article-title":"Immune regulatory genes are major genetic factors to behcet disease: systematic review","volume":"12","author":"Deng","year":"2018","journal-title":"Open Rheumatol J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/art.24642","article-title":"HLA-B51\/B5 and the risk of Behcet's disease: a systematic review and meta-analysis of case-control genetic association studies","volume":"61","author":"de Menthon","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B26","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/ng.625","article-title":"Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease","volume":"42","author":"Remmers","year":"2010","journal-title":"Nat Genet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/ng.624","article-title":"Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci","volume":"42","author":"Mizuki","year":"2010","journal-title":"Nat Genet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/rheumatology\/ker428","article-title":"Relationships of HLA-B51 or B5 genotype with Behcet's disease clinical characteristics: systematic review and meta-analyses of observational studies","volume":"51","author":"Maldini","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3109\/09273948.2015.1136422","article-title":"HLA-B51 Carriers are Susceptible to Ocular Symptoms of Behcet Disease and the Association between the Two Becomes Stronger towards the East along the Silk Road: A Literature Survey","volume":"25","author":"Horie","year":"2017","journal-title":"Ocular Immunol Inflammation"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4137\/CMAMD.S39879","article-title":"Genetic association of HLA-A*26, -A*31, and -B*51 with behcet's disease in saudi patients","volume":"9","author":"Al-Okaily","year":"2016","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord"},{"key":"B31","article-title":"[Behcet's disease with ocular involvement in Taiwan: a joint survey of six major ophthalmological departments]","volume":"89","author":"Chung","year":"1990","journal-title":"J Formos Med Assoc"},{"key":"B32","article-title":"[Four-digit allele genotyping of HLA-A and HLA-B genes in Japanese patients with Behcet's disease (BD) by a PCR-SSOP-luminex method and stratification analysis according to each major symptom of BD]","volume":"112","author":"Kamiishi","year":"2008","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.1997.38.6.333","article-title":"Molecular genetics (HLA) of Behcet's disease","volume":"38","author":"Mizuki","year":"1997","journal-title":"Yonsei Med J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1038\/s41598-019-40824-y","article-title":"The association analysis between HLA-A*26 and Behcet's disease","volume":"9","author":"Nakamura","year":"2019","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1406575111","article-title":"Behcet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity","volume":"111","author":"Ombrello","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2551","article-title":"Identification of multiple independent susceptibility loci in the HLA region in Behcet's disease","volume":"45","author":"Hughes","year":"2013","journal-title":"Nat Genet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"R49","DOI":"10.1186\/ar3292","article-title":"Associations between the HLA-A polymorphism and the clinical manifestations of Behcet's disease","volume":"13","author":"Kang","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2013.06.036","article-title":"Genetic and non-genetic factors affecting the visual outcome of ocular Behcet's disease","volume":"74","author":"Kang","year":"2013","journal-title":"Hum Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13049","article-title":"Is Behcet's disease a 'class 1-opathy'? The role of HLA-B*51 in the pathogenesis of Behcet's disease","volume":"191","author":"Giza","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"B40","article-title":"Genetic association of HLA-A*2601 with ocular Behcet's disease in Japanese patients","volume":"28","author":"Kaburaki","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108571","article-title":"Genetics of Behcet disease inside and outside the MHC","volume":"69","author":"Meguro","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1399-0039.1997.tb02835.x","article-title":"A strong association between HLA-B*5101 and Behcet's disease in Greek patients","volume":"50","author":"Mizuki","year":"1997","journal-title":"Tissue Antigens"},{"key":"B43","doi-asserted-by":"publisher","first-page":"R145","DOI":"10.1186\/ar4328","article-title":"HLA and non-HLA genes in Behcet's disease: a multicentric study in the Spanish population","volume":"15","author":"Montes-Cano","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161305","article-title":"Genetic analysis with the immunochip platform in behcet disease. Identification of residues associated in the HLA class I region and new susceptibility loci","volume":"11","author":"Ortiz-Fernandez","year":"2016","journal-title":"PloS One"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.08.013","article-title":"The immunogenetics of Behcet's disease: A comprehensive review","volume":"64","author":"Takeuchi","year":"2015","journal-title":"J Autoimmun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-92616-8_12","article-title":"The immunogenetics of behcet's disease","volume":"1367","author":"Y\u0131lmaz","year":"2022","journal-title":"Adv Exp Med Biol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1684\/ecn.2009.0209","article-title":"Proinflammatory cytokine gene polymorphisms in Behcet's disease","volume":"21","author":"Amirzargar","year":"2010","journal-title":"Eur Cytokine network"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/ni1089","article-title":"Post-proteasomal antigen processing for major histocompatibility complex class I presentation","volume":"5","author":"Rock","year":"2004","journal-title":"Nat Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2520","article-title":"Genome-wide association analysis identifies new susceptibility loci for Behcet's disease and epistasis between HLA-B*51 and ERAP1","volume":"45","author":"Kirino","year":"2013","journal-title":"Nat Genet"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5357.1737","article-title":"Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells","volume":"279","author":"Groh","year":"1998","journal-title":"Science"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3892\/br.2016.644","article-title":"A meta-analysis of the association between Behcet's disease and MICA-A6","volume":"4","author":"Wei","year":"2016","journal-title":"BioMed Rep"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.4.1298","article-title":"Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behcet disease","volume":"94","author":"Mizuki","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2002.17.3.366","article-title":"Association of MICA polymorphism with HLA-B51 and disease severity in Korean patients with Behcet's disease","volume":"17","author":"Park","year":"2002","journal-title":"J Korean Med Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1080\/15622970802626580","article-title":"Interleukin-10 gene promoter polymorphism in patients with schizophrenia in a region of East Turkey","volume":"10","author":"Ozbey","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2006.11.010","article-title":"IL-10 genotype analysis in patients with Behcet's disease","volume":"68","author":"Wallace","year":"2007","journal-title":"Hum Immunol"},{"key":"B56","article-title":"Cytokine gene polymorphisms in Behcet's disease and their association with clinical and laboratory findings","volume":"27","author":"Dilek","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.imlet.2017.12.008","article-title":"Molecular analysis of interleukin-10 gene polymorphisms in patients with Behcet's disease","volume":"194","author":"Afkari","year":"2018","journal-title":"Immunol Lett"},{"key":"B58","first-page":"589","article-title":"Interleukin-10 gene polymorphisms are associated with Behcet's disease but not with Vogt-Koyanagi-Harada syndrome in the Chinese Han population","volume":"21","author":"Hu","year":"2015","journal-title":"Mol Vis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2013.11.009","article-title":"IL10 polymorphisms associated with Behcet's disease in Chinese Han","volume":"75","author":"Wu","year":"2014","journal-title":"Hum Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.119420","article-title":"IL-23R gene confers susceptibility to Behcet's disease in a Chinese Han population","volume":"69","author":"Jiang","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3786","article-title":"Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behcet's disease susceptibility","volume":"49","author":"Takeuchi","year":"2017","journal-title":"Nat Genet"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.11.026","article-title":"New insights into the pathogenesis of Behcet's disease","volume":"11","author":"Pineton de Chambrun","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B63","article-title":"Behcet's disease-like symptoms induced by the Herpes simplex virus in ICR mice","volume":"8","author":"Sohn","year":"1998","journal-title":"Eur J Dermatol EJD"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2008.180","article-title":"Interleukin-6 small interfering RNA improved the herpes simplex virus-induced systemic inflammation in vivo Behcet's disease-like mouse model","volume":"16","author":"Shim","year":"2009","journal-title":"Gene Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2006.02.014","article-title":"[Pathophysiology of behcet's disease]","volume":"27","author":"Amoura","year":"2006","journal-title":"La Rev medecine interne"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.151.4.2273","article-title":"T cell epitope expression of mycobacterial and homologous human 65-kilodalton heat shock protein peptides in short term cell lines from patients with Behcet's disease","volume":"151","author":"Pervin","year":"1993","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1521-4141(199808)28:08<2444::AID-IMMU2444>3.0.CO;2-N","article-title":"Experimental mucosal induction of uveitis with the 60-kDa heat shock protein-derived peptide 336-351","volume":"28","author":"Hu","year":"1998","journal-title":"Eur J Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1006\/exer.1998.0574","article-title":"HSP-derived peptides inducing uveitis and IgG and IgA antibodies","volume":"67","author":"Uchio","year":"1998","journal-title":"Exp Eye Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"681956","DOI":"10.1155\/2011\/681956","article-title":"Behcet's disease (Adamantiades-Behcet's disease)","volume":"2011","author":"Kaneko","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4313","article-title":"Immune responses to interphotoreceptor retinoid-binding protein and S-antigen in Behcet's patients with uveitis","volume":"51","author":"Takeuchi","year":"2010","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"B71","article-title":"S-antigen specific T helper type 1 response is present in Behcet's disease","volume":"14","author":"Zhao","year":"2008","journal-title":"Mol Vis"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-006-0281-6","article-title":"Immunopathogenesis of Behcet's disease with special emphasize on the possible role of antigen presenting cells","volume":"27","author":"Pay","year":"2007","journal-title":"Rheumatol Int"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1080\/08830180212068","article-title":"Experimental autoimmune uveitides: multiple antigens, diverse diseases","volume":"21","author":"Adamus","year":"2002","journal-title":"Int Rev Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4835(91)90245-A","article-title":"Interphotoreceptor retinoid-binding protein (IRBP) in progressive rod-cone degeneration (prcd)\u2013biochemical, immunocytochemical and immunologic studies","volume":"53","author":"Wiggert","year":"1991","journal-title":"Exp Eye Res"},{"key":"B75","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.140.5.1490","article-title":"A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens","volume":"140","author":"Caspi","year":"1988","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B76","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3109\/02713689208999512","article-title":"Epitopes and idiotypes in experimental autoimmune uveitis: a review","author":"Dua","year":"1992","journal-title":"Curr Eye Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3109\/02713688809001879","article-title":"Human IRBP: characterization of uveitopathogenic sites","volume":"7","author":"Donoso","year":"1988","journal-title":"Curr Eye Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v25.i5.20","article-title":"Differentiation of NK1 and NK2 cells","volume":"25","author":"Kimura","year":"2005","journal-title":"Crit Rev Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12939","article-title":"Circulating NK cells and their subsets in Behcet's disease","volume":"188","author":"Hasan","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.9.6133","article-title":"CD8brightCD56+ T cells are cytotoxic effectors in patients with active Behcet's uveitis","volume":"175","author":"Ahn","year":"2005","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.72.6.1117","article-title":"Diminution of experimental autoimmune uveoretinitis (EAU) in mice depleted of NK cells","volume":"72","author":"Kitaichi","year":"2002","journal-title":"J leukocyte Biol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"R80","DOI":"10.1186\/ar3005","article-title":"Natural killer cells control a T-helper 1 response in patients with Behcet's disease","volume":"12","author":"Yamaguchi","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-0825.2005.01185.x","article-title":"Diversity of gammadelta T cells in patients with Behcet's disease is indicative of polyclonal activation","volume":"12","author":"Freysdottir","year":"2006","journal-title":"Oral Dis"},{"key":"B84","doi-asserted-by":"publisher","first-page":"R109","DOI":"10.1186\/ar3043","article-title":"Phenotype and functional changes of Vgamma9\/Vdelta2 T lymphocytes in Behcet's disease and the effect of infliximab on Vgamma9\/Vdelta2 T cell expansion, activation and cytotoxicity","volume":"12","author":"Accardo-Palumbo","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B85","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1067\/mlc.2003.1","article-title":"Expansion of gammadelta T-cells in Behcet's disease: role of disease activity and microbial flora in oral ulcers","volume":"141","author":"Bank","year":"2003","journal-title":"J Lab Clin Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S0165-5728(02)00208-4","article-title":"Vgamma9Vdelta2 T cells recovered from eyes of patients with Behcet's disease recognize non-peptide prenyl pyrophosphate antigens","volume":"130","author":"Verjans","year":"2002","journal-title":"J neuroimmunology"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M008684200","article-title":"Isopentenyl pyrophosphate, a mycobacterial non-peptidic antigen, triggers delayed and highly sustained signaling in human gamma delta T lymphocytes without inducing eown-modulation of T cell antigen receptor","volume":"276","author":"Lafont","year":"2001","journal-title":"J Biol Chem"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6758","article-title":"Activated gammadelta T cells promote the activation of uveitogenic T cells and exacerbate EAU development","volume":"52","author":"Nian","year":"2011","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2003.tb00442.x","article-title":"Serum levels of IL-4, IL-10, IL-12, IL-13 and IFN-gamma in behcet's disease","volume":"30","author":"Aridogan","year":"2003","journal-title":"J Dermatol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.04.016","article-title":"Intraocular cytokine environment in active Behcet uveitis","volume":"142","author":"Ahn","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.01.014","article-title":"Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis","volume":"139","author":"El-Asrar","year":"2011","journal-title":"Clin Immunol (Orlando Fla)"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.08.019","article-title":"Th17 cells in inflammation and autoimmunity","volume":"13","author":"Singh","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-1390","article-title":"Upregulated IL-23 and IL-17 in Behcet patients with active uveitis","volume":"49","author":"Chi","year":"2008","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6070074","article-title":"The role of th17 cells in the pathogenesis of behcet's disease","volume":"6","author":"Nanke","year":"2017","journal-title":"J Clin Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.881720","article-title":"Expression of th-17 and RORgammat mRNA in behcet's disease","volume":"17","author":"Hamzaoui","year":"2011","journal-title":"Med Sci Monit"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/ni1488","article-title":"IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways","volume":"8","author":"Zhou","year":"2007","journal-title":"Nat Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.05.029","article-title":"Critical role of IL-21 in modulating TH17 and regulatory T cells in Behcet disease","volume":"128","author":"Geri","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1018182108","article-title":"Key role for IL-21 in experimental autoimmune uveitis","volume":"108","author":"Wang","year":"2011","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1767","article-title":"Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells","volume":"10","author":"Duhen","year":"2009","journal-title":"Nat Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202677","article-title":"Role of IL-22- and TNF-alpha-producing Th22 cells in uveitis patients with Behcet's disease","volume":"190","author":"Sugita","year":"2013","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059009","article-title":"Increased expression of IL-22 is associated with disease activity in Behcet's disease","volume":"8","author":"Cai","year":"2013","journal-title":"PloS One"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2011.01.012","article-title":"RORC and Foxp3 axis in cerebrospinal fluid of patients with neuro-Behcet's disease","volume":"233","author":"Hamzaoui","year":"2011","journal-title":"J neuroimmunology"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.01.017","article-title":"Emerging role of IL-35 in inflammatory autoimmune diseases","volume":"17","author":"Su","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/1043-4666(92)90028-P","article-title":"The role of cytokines in the pathogenesis of inflammatory eye disease","volume":"4","author":"Wakefield","year":"1992","journal-title":"Cytokine"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.08.006","article-title":"Insights into IL-37, the role in autoimmune diseases","volume":"14","author":"Xu","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B106","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.imlet.2015.08.001","article-title":"Interleukin-37 expression is decreased in Behcet's disease and is associated with inflammation","volume":"167","author":"Bouali","year":"2015","journal-title":"Immunol Lett"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/nm1585","article-title":"TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27\/STAT1","volume":"13","author":"Amadi-Obi","year":"2007","journal-title":"Nat Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/ni1540","article-title":"Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells","volume":"8","author":"Fitzgerald","year":"2007","journal-title":"Nat Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/j.1365-2567.2010.03379.x","article-title":"Retinal cells suppress intraocular inflammation (uveitis) through production of interleukin-27 and interleukin-10","volume":"132","author":"Lee","year":"2011","journal-title":"Immunology"},{"key":"B110","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/01.bor.0000197995.27579.9b","article-title":"New approaches in the treatment of Adamantiades-Behcet's disease","volume":"18","author":"Pipitone","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","article-title":"Current concepts in the etiology and treatment of Behcet disease","volume":"50","author":"Evereklioglu","year":"2005","journal-title":"Survey Ophthalmol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh311","article-title":"Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease","volume":"43","author":"Treusch","year":"2004","journal-title":"Rheumatol (Oxford)"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2011.0238","article-title":"Results of interferon alpha-2a therapy in patients with Behcet's disease","volume":"28","author":"Yal\u00e7inda\u011f","year":"2012","journal-title":"J ocular Pharmacol Ther Off J Assoc Ocular Pharmacol Ther"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-014-2856-3","article-title":"Anti-interferon alpha antibodies and autoantibodies in patients with Beh\u00e7et's disease uveitis treated with recombinant human interferon alpha-2a","volume":"253","author":"Aydinoglu-Candan","year":"2015","journal-title":"Graefe's Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie"},{"key":"B115","first-page":"3","article-title":"One year in review 2017: Beh\u00e7et's syndrome","author":"Hatemi","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1076\/ocii.8.4.293.6453","article-title":"Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet's disease","volume":"8","author":"Wechsler","year":"2000","journal-title":"Ocular Immunol Inflammation"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.5.492","article-title":"Effects of interferon alpha treatment on the clinical course of refractory Behcet's disease: an open study","volume":"62","author":"Calguneri","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1007\/0-306-48382-3_103","article-title":"Interferon alfa-2a in the treatment of ocular Adamantiades-Behcet's disease","volume":"528","author":"Krause","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1007\/0-306-48382-3_104","article-title":"Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behcet's disease with sight-threatening retinal vasculitis","volume":"528","author":"Kotter","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-006-0346-y","article-title":"Results of interferon-alfa therapy in patients with Behcet uveitis","volume":"244","author":"Tugal-Tutkun","year":"2006","journal-title":"Graefe's Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.101550","article-title":"Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients","volume":"91","author":"Bodaghi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.ajo.2008.08.038","article-title":"Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease","volume":"146","author":"Gueudry","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.11.022","article-title":"Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet's uveitis refractory to conventional treatments","volume":"117","author":"Sobaci","year":"2010","journal-title":"Ophthalmology"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1002\/art.27581","article-title":"Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet's disease","volume":"62","author":"Deuter","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.3","article-title":"Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Beh\u00e7et uveitis","volume":"129","author":"Onal","year":"2011","journal-title":"Arch Ophthalmol (Chicago Ill 1960)"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2015.1133835","article-title":"Interferon alpha-2a therapy in patients with refractory beh\u00e7et uveitis","volume":"25","author":"Hasanreisoglu","year":"2017","journal-title":"Ocular Immunol Inflammation"},{"key":"B127","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/09273948.2016.1206204","article-title":"Long-term efficacy of interferon in severe uveitis associated with beh\u00e7et disease","volume":"25","author":"Diwo","year":"2017","journal-title":"Ocular Immunol Inflammation"},{"key":"B128","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin Arthritis rheumatism"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.158840","article-title":"Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease","volume":"94","author":"Yamada","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Behcet's disease: Multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J Autoimmun"},{"key":"B131","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/09273948.2016.1239746","article-title":"Efficacy of infliximab for early remission induction in refractory uveoretinitis associated with behcet disease: A 2-year follow-up study","volume":"25","author":"Keino","year":"2017","journal-title":"Ocular Immunol Inflamm"},{"key":"B132","article-title":"Infliximab for uveitis of Beh\u00e7et's syndrome: a trend for earlier initiation","author":"Guzelant","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-1213-z","article-title":"One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behcet's disease refractory to standard immunosuppressive drugs","volume":"31","author":"Giardina","year":"2011","journal-title":"Rheumatol Int"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2014.138","article-title":"Long-term efficacy of infliximab on background vascular leakage in patients with Behcet's disease","volume":"28","author":"Keino","year":"2014","journal-title":"Eye (Lond)"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.04.042","article-title":"Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behcet's disease: a multicenter study","volume":"121","author":"Takeuchi","year":"2014","journal-title":"Ophthalmology"},{"key":"B136","article-title":"Adalimumab for treatment of severe Beh\u00e7et's uveitis: a retrospective long-term follow-up study","volume":"32","author":"Interlandi","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1002\/art.39667","article-title":"Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: A multicenter study from the french uveitis network","volume":"68","author":"Vallet","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3480-x","article-title":"Efficacy and safety of adalimumab in Beh\u00e7et's disease-related uveitis: a multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III","volume":"125","author":"Suhler","year":"2018","journal-title":"Ophthalmology"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2012.741744","article-title":"Beh\u00e7et disease-associated uveitis successfully treated with golimumab","volume":"21","author":"Mesquida","year":"2013","journal-title":"Ocular Immunol Inflammation"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-008-0857-5","article-title":"Efficacy of etanercept in the treatment of a patient with Behcet's disease","volume":"27","author":"Curigliano","year":"2008","journal-title":"Clin Rheumatol"},{"key":"B144","first-page":"729","article-title":"Successful treatment of resistant Behcet's disease with etanercept","volume":"23","author":"Atzeni","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.11.031","article-title":"A case of mucocutaneous Behcet's disease responding to etanercept","volume":"52","author":"Sommer","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-019-02035-1","article-title":"Update on the treatment of Behcet's syndrome","volume":"14","author":"Esatoglu","year":"2019","journal-title":"Intern Emerg Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2017.05.002","article-title":"Ustekinumab for behcet's disease","volume":"82","author":"Mirouse","year":"2017","journal-title":"J Autoimmun"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3506-4","article-title":"Interleukin (IL)-1 inhibition with anakinra and canakinumab in Beh\u00e7et's disease-related uveitis: a multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2443-8","article-title":"Anakinra treatment in drug-resistant Behcet's disease: a case series","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin Rheumatol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"107421","DOI":"10.1155\/2014\/107421","article-title":"Biological treatments in Behcet's disease: beyond anti-TNF therapy","volume":"2014","author":"Caso","year":"2014","journal-title":"Mediators Inflammation"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1159\/000358125","article-title":"Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behcet's disease: a case series","volume":"228","author":"Vitale","year":"2014","journal-title":"Dermatology"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex480","article-title":"Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Beh\u00e7et's disease: multicentre retrospective study","volume":"57","author":"Atienza-Mateo","year":"2018","journal-title":"Rheumatol (Oxford)"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2017.1355471","article-title":"Tocilizumab for the treatment of behcet uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy","volume":"26","author":"Eser Ozturk","year":"2018","journal-title":"Ocular Immunol Inflammation"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.11.012","article-title":"Tocilizumab in severe and refractory Behcet's disease: Four cases and literature review","volume":"45","author":"Deroux","year":"2016","journal-title":"Semin Arthritis rheumatism"},{"key":"B155","doi-asserted-by":"publisher","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202392","article-title":"Successful long-term triple disease control by ustekinumab in a patient with Behcet's disease, psoriasis and hidradenitis suppurativa","volume":"72","author":"Baerveldt","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17318","article-title":"Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials","volume":"180","author":"Langley","year":"2019","journal-title":"Br J Dermatol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.07.018","article-title":"Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn","volume":"4","author":"Vasiliauskas","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04617.x","article-title":"High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy","volume":"33","author":"Zelinkova","year":"2011","journal-title":"Alimentary Pharmacol Ther"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.71","article-title":"Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy","volume":"104","author":"Kane","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00334-7","article-title":"Placental transport of immunoglobulin G","volume":"21","author":"Simister","year":"2003","journal-title":"Vaccine"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2011.05.009","article-title":"Safety of infliximab use during pregnancy","volume":"32","author":"Djokanovic","year":"2011","journal-title":"Reprod Toxicol (Elmsford NY)"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1002\/art.41191","article-title":"American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.cgh.2015.08.039","article-title":"Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy","volume":"14","author":"Broms","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.reprotox.2013.11.004","article-title":"Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study","volume":"43","author":"Diav-Citrin","year":"2014","journal-title":"Reprod Toxicol (Elmsford NY)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1206959\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T17:20:20Z","timestamp":1696094420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1206959\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":168,"alternative-id":["10.3389\/fimmu.2023.1206959"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1206959","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,29]]},"article-number":"1206959"}}